Translational Research in Neurology and Neuroscience 2010
Year: 2010
Type: article
Abstract: Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.
Source: Archives of Neurology
Institutions: VA North Texas Health Care System, University of California, San Francisco, TUM Klinikum, Texas Neurology, Heinrich Heine University Düsseldorf, University of Rostock, The Ohio State University, Case Western Reserve University, Technical University of Munich, The University of Texas Southwestern Medical Center, Ruhr University Bochum, Barzilai Medical Center, RTX (United States), Raytheon (United States), Wayne State University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1994357436